D04AX01 doxepin

DERMATOLOGICALS ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. Other antipruritics

非健保收載 TFDA 在效許可證 2 FDA 已核准 健保給付條款 1

台灣藥品與外觀

台灣食藥署在效西藥許可證 2 張;以下列出 2 個品項。

無外觀照
鹽酸多士平
無外觀照
多士平鹽酸鹽

資料來源:食藥署「西藥許可證」+「藥品 ATC 碼」+「藥品外觀」+「藥品仿單或外盒」開放資料。外觀照與仿單連結指向食藥署原始檔。

適應症

台灣 TFDA 核准適應症

  1. 憂鬱症治療藥。
  2. 治療憂鬱藥。

美國 FDA 適應症(英文原文對照)

美國 FDA 核准成分 doxepin hydrochloride (商品名 DOXEPIN HYDROCHLORIDE / Doxepin / Doxepin HCL / Doxepin Hydrochloride / Doxepin hydrochloride) · 仿單更新 2026-01-09

INDICATIONS AND USAGE Doxepin Hydrochloride Capsules, USP are recommended for the treatment of: 1. Psychoneurotic patients with depression and/or anxiety. 2. Depression and/or anxiety associated with alcoholism (not to be taken concomitantly with alcohol). 3. Depression and/or anxiety associated with organic disease (the possibility of drug interaction should be considered if the patient is receiving other drugs concomitantly). 4. Psychotic depressive disorders with associated anxiety including involutional depression and manic-depressive disorders. The target symptoms of psychoneurosis that respond particularly well to doxepin hydrochloride capsules include anxiety, tension, depression, somatic symptoms and concerns, sleep disturbances, guilt, lack of energy, fear, apprehension and worry. Clinical experience has shown that doxepin hydrochloride capsules are safe and well tolerated even in the elderly patient. Owing to lack of clinical experience in the pediatric population, doxepin hydrochloride capsules are not recommended for use in children under 12 years of age.

資料來源:食藥署西藥許可證適應症(中文)、openFDA US SPL(英文,僅供對照)。

健保給付規定

直接適用條款

§ 13.7 Doxepin HCl cream (如Ichderm):(88/6/1)
皮膚科製劑 › Doxepin HCl cream (如Ichderm):(88/6/1)
Doxepin HCl cream (如Ichderm):(88/6/1)
限成人使用,每次處方不超過七天。
歷史演變(1 次異動)
生效日異動說明
88/6/1legacy_boan_parsed:ch13.txt

實證補充

本藥品尚無實證補充整理(未來新增 Review/指引知識時補列)。


台灣藥品與適應症:食藥署西藥許可證+ATC+外觀+仿單開放資料 · FDA:openFDA US SPL · 健保給付:健保署「全民健康保險藥品給付規定」(更新日 2026-06-09)· 實證補充:人工彙整。 本頁為資訊整理,實際給付與適應症以主管機關公告為準。